The Motley Fool

UBS claims it’s time to sell your Cochlear (ASX:COH) shares

Cochlear Limited (ASX: COH) manufactures and distributes cochlear implantable devices for hearing impaired patients in Australia and more than 20 countries. 

UBS has updated its modelling of crucial drivers of Cochlear shares, resulting in minor changes to forecast earnings per share (EPS) by -3%. Forecast EPS growth will average 10.5% over the next three years.

Based on management’s comments at a recent investor day around operating expenditure to increase future market penetration and maintain net profit margins, UBS sees downside risk to FY19/FY20 Bloomberg’s consensus Net Profit After Tax.  

UBS has increased its share price target to A$170, up from $150. The share price is up 37% in a year, and at the current share price of $194, the company is a sell according to UBS.

Cochlear is trading on a forward price-earnings-ratio of 46x, which is a premium to the Health Care Equipment & Services industry median of  19.8x. 

This “Holy Grail” Technology Could Produce World’s First Trillionaire

One of the world’s richest people is sounding the alarm on what could be a trillion-dollar technology.

And when a tech billionaire – several times over – speaks, it pays to listen.

This could be your chance to get in on the ground floor!

Click here to discover a $19.9 trillion dollar idea — hidden in plain sight!

Motley Fool contributor Rosemary Steinfort has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.